Annual EBIT
-$46.92 M
+$39.53 M+45.72%
December 31, 2023
Summary
- As of February 8, 2025, TBPH annual earnings before interest & taxes is -$46.92 million, with the most recent change of +$39.53 million (+45.72%) on December 31, 2023.
- During the last 3 years, TBPH annual EBIT has risen by +$247.88 million (+84.08%).
- TBPH annual EBIT is now -390.02% below its all-time high of -$9.57 million, reached on December 31, 2012.
Performance
TBPH EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$9.42 M
+$5.16 M+35.36%
September 30, 2024
Summary
- As of February 8, 2025, TBPH quarterly earnings before interest & taxes is -$9.42 million, with the most recent change of +$5.16 million (+35.36%) on September 30, 2024.
- Over the past year, TBPH quarterly EBIT has dropped by -$2.45 million (-35.10%).
- TBPH quarterly EBIT is now -114.48% below its all-time high of -$4.39 million, reached on December 31, 2023.
Performance
TBPH Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$38.16 M
-$2.45 M-6.85%
September 30, 2024
Summary
- As of February 8, 2025, TBPH TTM earnings before interest & taxes is -$38.16 million, with the most recent change of -$2.45 million (-6.85%) on September 30, 2024.
- Over the past year, TBPH TTM EBIT has increased by +$18.07 million (+32.13%).
- TBPH TTM EBIT is now -18.62% below its all-time high of -$32.17 million, reached on March 31, 2013.
Performance
TBPH TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TBPH EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +45.7% | -35.1% | +32.1% |
| 3 y3 years | +84.1% | +82.4% | +85.9% |
| 5 y5 years | +78.2% | +91.3% | +87.0% |
TBPH EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +81.7% | -114.5% | +83.1% | -9.8% | +82.5% |
| 5 y | 5-year | at high | +84.1% | -114.5% | +91.3% | -9.8% | +87.0% |
| alltime | all time | -390.0% | +84.1% | -114.5% | +91.3% | -18.6% | +87.0% |
Theravance Biopharma EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.42 M(-35.4%) | -$38.16 M(+6.9%) |
| Jun 2024 | - | -$14.58 M(+49.2%) | -$35.72 M(+2.8%) |
| Mar 2024 | - | -$9.77 M(+122.5%) | -$34.76 M(-25.9%) |
| Dec 2023 | -$46.92 M(-45.7%) | -$4.39 M(-37.0%) | -$46.92 M(-16.6%) |
| Sep 2023 | - | -$6.97 M(-48.8%) | -$56.23 M(-11.8%) |
| Jun 2023 | - | -$13.62 M(-37.9%) | -$63.74 M(-9.9%) |
| Mar 2023 | - | -$21.93 M(+60.0%) | -$70.78 M(-17.8%) |
| Dec 2022 | -$86.45 M(-66.3%) | -$13.71 M(-5.3%) | -$86.07 M(-32.9%) |
| Sep 2022 | - | -$14.48 M(-29.9%) | -$128.19 M(-23.4%) |
| Jun 2022 | - | -$20.66 M(-44.5%) | -$167.33 M(-10.8%) |
| Mar 2022 | - | -$37.22 M(-33.3%) | -$187.68 M(-13.8%) |
| Dec 2021 | -$256.68 M(-12.9%) | -$55.83 M(+4.1%) | -$217.80 M(-19.4%) |
| Sep 2021 | - | -$53.62 M(+30.7%) | -$270.37 M(-3.0%) |
| Jun 2021 | - | -$41.01 M(-39.1%) | -$278.73 M(-3.6%) |
| Mar 2021 | - | -$67.34 M(-37.9%) | -$289.18 M(-1.9%) |
| Dec 2020 | -$294.80 M(+40.5%) | -$108.40 M(+74.9%) | -$294.80 M(+20.9%) |
| Sep 2020 | - | -$61.98 M(+20.4%) | -$243.92 M(+2.5%) |
| Jun 2020 | - | -$51.46 M(-29.5%) | -$237.86 M(+9.0%) |
| Mar 2020 | - | -$72.97 M(+26.8%) | -$218.14 M(+4.0%) |
| Dec 2019 | -$209.81 M(-2.7%) | -$57.52 M(+2.9%) | -$209.81 M(+4.0%) |
| Sep 2019 | - | -$55.91 M(+76.2%) | -$201.66 M(-1.0%) |
| Jun 2019 | - | -$31.74 M(-50.9%) | -$203.70 M(-6.3%) |
| Mar 2019 | - | -$64.64 M(+30.9%) | -$217.44 M(+0.9%) |
| Dec 2018 | -$215.60 M | -$49.37 M(-14.8%) | -$215.60 M(-11.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$57.95 M(+27.5%) | -$244.03 M(-2.4%) |
| Jun 2018 | - | -$45.47 M(-27.6%) | -$249.95 M(-6.8%) |
| Mar 2018 | - | -$62.81 M(-19.3%) | -$268.17 M(+1.9%) |
| Dec 2017 | -$263.16 M(+46.9%) | -$77.80 M(+21.8%) | -$263.16 M(+8.4%) |
| Sep 2017 | - | -$63.87 M(+0.3%) | -$242.73 M(+14.5%) |
| Jun 2017 | - | -$63.70 M(+10.2%) | -$212.01 M(+8.4%) |
| Mar 2017 | - | -$57.80 M(+0.8%) | -$195.50 M(+9.1%) |
| Dec 2016 | -$179.16 M(-1.2%) | -$57.36 M(+73.0%) | -$179.16 M(+1.3%) |
| Sep 2016 | - | -$33.15 M(-29.8%) | -$176.94 M(-5.3%) |
| Jun 2016 | - | -$47.19 M(+13.8%) | -$186.88 M(+1.0%) |
| Mar 2016 | - | -$41.46 M(-24.8%) | -$184.99 M(+2.1%) |
| Dec 2015 | -$181.27 M(-21.4%) | -$55.14 M(+28.0%) | -$181.27 M(-4.6%) |
| Sep 2015 | - | -$43.09 M(-4.9%) | -$190.01 M(-3.5%) |
| Jun 2015 | - | -$45.29 M(+20.0%) | -$196.98 M(-5.5%) |
| Mar 2015 | - | -$37.74 M(-40.9%) | -$208.39 M(-9.7%) |
| Dec 2014 | -$230.67 M(+47.6%) | -$63.89 M(+27.6%) | -$230.67 M(+9.4%) |
| Sep 2014 | - | -$50.06 M(-11.7%) | -$210.87 M(+4.5%) |
| Jun 2014 | - | -$56.71 M(-5.5%) | -$201.88 M(+9.6%) |
| Mar 2014 | - | -$60.02 M(+36.2%) | -$184.13 M(+17.8%) |
| Dec 2013 | -$156.28 M(+1532.2%) | -$44.08 M(+7.3%) | -$156.28 M(+39.3%) |
| Sep 2013 | - | -$41.08 M(+5.5%) | -$112.20 M(+57.8%) |
| Jun 2013 | - | -$38.95 M(+21.1%) | -$71.13 M(+121.1%) |
| Mar 2013 | - | -$32.17 M | -$32.17 M |
| Dec 2012 | -$9.57 M | - | - |
FAQ
- What is Theravance Biopharma annual earnings before interest & taxes?
- What is the all time high annual EBIT for Theravance Biopharma?
- What is Theravance Biopharma annual EBIT year-on-year change?
- What is Theravance Biopharma quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Theravance Biopharma?
- What is Theravance Biopharma quarterly EBIT year-on-year change?
- What is Theravance Biopharma TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Theravance Biopharma?
- What is Theravance Biopharma TTM EBIT year-on-year change?
What is Theravance Biopharma annual earnings before interest & taxes?
The current annual EBIT of TBPH is -$46.92 M
What is the all time high annual EBIT for Theravance Biopharma?
Theravance Biopharma all-time high annual earnings before interest & taxes is -$9.57 M
What is Theravance Biopharma annual EBIT year-on-year change?
Over the past year, TBPH annual earnings before interest & taxes has changed by +$39.53 M (+45.72%)
What is Theravance Biopharma quarterly earnings before interest & taxes?
The current quarterly EBIT of TBPH is -$9.42 M
What is the all time high quarterly EBIT for Theravance Biopharma?
Theravance Biopharma all-time high quarterly earnings before interest & taxes is -$4.39 M
What is Theravance Biopharma quarterly EBIT year-on-year change?
Over the past year, TBPH quarterly earnings before interest & taxes has changed by -$2.45 M (-35.10%)
What is Theravance Biopharma TTM earnings before interest & taxes?
The current TTM EBIT of TBPH is -$38.16 M
What is the all time high TTM EBIT for Theravance Biopharma?
Theravance Biopharma all-time high TTM earnings before interest & taxes is -$32.17 M
What is Theravance Biopharma TTM EBIT year-on-year change?
Over the past year, TBPH TTM earnings before interest & taxes has changed by +$18.07 M (+32.13%)